Iranian Military: U.S. and Israel's Attempt to Control the Strait of Hormuz Will Never Succeed
Svmuu News Ibrahim Zolfaghari, spokesperson for the Khatam al-Anbiya Central Headquarters of the Iranian Armed Forces, stated that the strategic miscalculations by the United States and Israel regarding the situation in Iran are leading them toward destruction, and any attempt to control the Strait of Hormuz will come to nothing. The spokesperson said that the miscalculations by the leaders of the United States and Israel have led them to try to assess Iran's strength using material metrics. He emphasized that this erroneous calculation has prevented them from foreseeing the powerful resistance demonstrated by the Iranian people and the armed forces. The spokesperson stated that the U.S. and Israel are attempting to force Iran to surrender through propaganda warfare, showcasing so-called advanced weaponry and equipment, and assassinating Iranian children, women, scientists, and senior commanders. He made it clear that the U.S. and Israel's delusion of controlling the Strait of Hormuz is a wish that will never be realized. (CCTV News)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
4
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
7
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
8
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
9
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading









